Frontiers in medicine · 2026
Systematic analysis of echinocandin-associated adverse reactions using the FAERS database: identification of unique DRESS and resistance signals.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Xue, Nie Ji, Xie Yuanchun, Ran Ya, Zhou Hanhan, Li Bin
Аннотация
AIM: This pharmacovigilance study analyzed echinocandin-related adverse events (AEs) using the FDA Adverse Event Reporting System (FAERS) database to identify agent-specific safety signals and inform clinical decision-making.
METHODS: AE reports were extracted from FAERS covering Q1 2004 to Q4 2025. Four disproportionality algorithms-reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC025), and empirical Bayesian geometric mean (EBGM05)-were applied. Positive signals were defined when all four methods yielded positive results.
RESULTS: A total of 5,298 cases with echinocandins as the primary suspect drug were included. Caspofungin showed unique association with DRESS syndrome (ROR = 16.62, IC025 = 3.21). Exceptionally strong resistance signals were detected for caspofungin ("pathogen resistance": ROR = 68.83; "drug resistance": ROR = 22.32) and micafungin ("bronchopulmonary aspergillosis": ROR = 71.99; "Candida infection": ROR = 23.93). Hepatobiliary signals included cholestasis (ROR = 24.97) and alkaline phosphatase increase (ROR = 19.10) for caspofungin, with similar signals observed for micafungin and anidulafungin.
CONCLUSION: This pharmacovigilance study identified two clinically significant signals: DRESS as a unique safety concern for caspofungin, and striking resistance signals for caspofungin and micafungin. These findings emphasize the need for vigilant monitoring during echinocandin therapy and reinforce antifungal stewardship.
METHODS: AE reports were extracted from FAERS covering Q1 2004 to Q4 2025. Four disproportionality algorithms-reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC025), and empirical Bayesian geometric mean (EBGM05)-were applied. Positive signals were defined when all four methods yielded positive results.
RESULTS: A total of 5,298 cases with echinocandins as the primary suspect drug were included. Caspofungin showed unique association with DRESS syndrome (ROR = 16.62, IC025 = 3.21). Exceptionally strong resistance signals were detected for caspofungin ("pathogen resistance": ROR = 68.83; "drug resistance": ROR = 22.32) and micafungin ("bronchopulmonary aspergillosis": ROR = 71.99; "Candida infection": ROR = 23.93). Hepatobiliary signals included cholestasis (ROR = 24.97) and alkaline phosphatase increase (ROR = 19.10) for caspofungin, with similar signals observed for micafungin and anidulafungin.
CONCLUSION: This pharmacovigilance study identified two clinically significant signals: DRESS as a unique safety concern for caspofungin, and striking resistance signals for caspofungin and micafungin. These findings emphasize the need for vigilant monitoring during echinocandin therapy and reinforce antifungal stewardship.